https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-01-10 / Oncotarget 2018 Feb;9(11):10110-10117
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-01-10 / Oncotarget 2018 Feb;9(11):10110-101172018-01-10 00:00:002018-01-10 00:00:00A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-06-05 / J Clin Oncol 35, 2017 (suppl; abstr 3089)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-06-05 / J Clin Oncol 35, 2017 (suppl; abstr 3089)2017-06-05 12:09:062019-07-17 12:09:34Association of autologous AdHER2 dendritic cell vaccination with antitumor activity and number of circulating tumor cells.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-04-07 / Breast 2017 Jun;33:159-165
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-04-07 / Breast 2017 Jun;33:159-1652017-04-07 00:00:002017-04-07 00:00:00Reirradiation for locally recurrent breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-03-13 / Sci Rep 2017 03;7:43961
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-03-13 / Sci Rep 2017 03;7:439612017-03-13 00:00:002017-03-13 00:00:00Optimizing non-invasive radiofrequency hyperthermia treatment for improving drug delivery in 4T1 mouse breast cancer model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-01-01 / Adv Exp Med Biol 2017;1026:315-330
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-01-01 / Adv Exp Med Biol 2017;1026:315-3302017-01-01 00:00:002017-01-01 00:00:00Progress in Vaccine Therapies for Breast Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-12-13 / Clin Cancer Res 2017 Jun;23(12):2961-2971
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-12-13 / Clin Cancer Res 2017 Jun;23(12):2961-29712016-12-13 00:00:002023-03-07 13:00:25Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2 DCIS Independent of Route: Results of Randomized Selection Design Trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-10-04 / Oncotarget 2016 Oct;7(40):65042-65051
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-10-04 / Oncotarget 2016 Oct;7(40):65042-650512016-10-04 00:00:002016-10-04 00:00:00Radiofrequency hyperthermia promotes the therapeutic effects on chemotherapeutic-resistant breast cancer when combined with heat shock protein promoter-controlled HSV-TK gene therapy: Toward imaging-guided interventional gene therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-07-21 / Onco Targets Ther 2016;9:4441-51
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-07-21 / Onco Targets Ther 2016;9:4441-512016-07-21 00:00:002023-03-07 11:15:56Targeting breast cancer stem cells by dendritic cell vaccination in humanized mice with breast tumor: preliminary results
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-07-01 / Oncoimmunology 2017;6(9):e1207032
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-07-01 / Oncoimmunology 2017;6(9):e12070322016-07-01 00:00:002016-07-01 00:00:00Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ER/HER2 early breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-17 / J Clin Oncol 36, 2018 (suppl; abstr e24000)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-17 / J Clin Oncol 36, 2018 (suppl; abstr e24000)2016-06-17 12:11:492019-07-17 12:12:15Anti-tumor efficacy of the Runx2-dendritic cell vaccine in triple-negative breast cancer in vitro.
